AI in Medicine News — 2026-09-30 (Wed)
Source links point to the original outlet. The AI Integrated Analysis is auto-generated from the headlines below only and is not intended to add facts beyond them. Not investment advice.
Latest news on AI and cancer treatment
Overview
There is a noticeable movement toward the use of AI in the field of diagnostic imaging (second lead breast imaging, liquid biopsy as a substitute for liver biopsy, and spatial biomarker analysis for pathology). In breast cancer, there were reports on stratification of recurrence risk, while in the drug discovery field, the focus was on preclinical and corporate trends such as antibody exploration and partnerships. Specific information regarding announcements of approval/designation by regulatory authorities (FDA/EMA/PMDA) and clinical trial registration is not within the scope of this collection.
Breast cancer
- Target: HR+/HER2- breast cancer patients. It was reported that the AI score extracted from MRI can stratify recurrence risk in addition to existing standard prognostic factors (tumor size, grade, etc.) [Vera Health]. There is only a single headline information, and the target size and verification method (retrospective/prospective, single center/multicenter) are unclear. - It was reported that some medical institutions are using AI to replace radiologists for the 2nd read of breast images [Radiology Business]. Efficacy indicators (sensitivity, specificity, etc.) are not listed in the heading. - Flatiron Health expands AI-powered real-world dataset targeting breast cancer and NSCLC to UK, Germany, and Japan [BioSpace] Expanding the data base rather than making clinical validity claims.
lung cancer
We only confirmed that NSCLC (non-small cell lung cancer) is included in the Flatiron Health real-world data expansion mentioned above. There are no headlines regarding new findings regarding specific diagnostic accuracy or treatment selection.
Malignant brain tumor
- Article reporting that optical (photonic) biosensors incorporating AI may be useful in detecting glioblastoma tissue [azosensors.com]. The clinical application stage is unclear from the headline (it is assumed to be at the technology development/basic research stage, but it is not stated). - "Sheinelle Jones Horrified by Convincing AI Fake Featuring Her Children" [Reality Tea] is entertainment news about AI-generated deep fakes and has nothing to do with cancer treatment or medical AI. It was determined that the data was collected in error and was excluded from the analysis.
Leukemia/lymphoma
No applicable information
Colon cancer/digestive organ
"Latest hospital AI deployments in Singapore and more briefs" [Healthcare IT News] is an overview article about the introduction of AI in hospitals in Singapore, but the headline does not contain any specific content specific to the detection of colorectal cancer or gastrointestinal cancer.
Rare cancer
No applicable information
Diagnosis/Pathology/Image
- The use of AI in liquid biopsies was reported as a "hot field" [GlobeNewswire, citybiz (BCC Research)]. This is a report on market and investment trends, and clinical data such as detection sensitivity are not listed in the headline. - Haga Bioscience and Imagenomix enter into partnership to utilize AI in spatial biomarker analysis in cancer pathology [Genome Web]. This is a technical partnership announcement, and there are no figures regarding clinical performance. - Diagnostic imaging AI company reports 15% headcount reduction and annual revenue growth to $28 million [Radiology Business]. This is management and business trends, not information on clinical effectiveness. - The adoption of AI for the second lead in breast imaging (same case as 2. above) was also featured in an industry summary article [Radiology Business]. In the same article, ``KOA (knee arthropathy) treatment using low-dose radiation therapy'' is not covered because it is unrelated to cancer.
Treatment selection/drug discovery
- It was reported that the pharmaceutical industry as a whole is moving to strengthen the use of AI to reduce costs and development times [Reuters]. This is an article about industry trends, with no description of individual drugs or stages. - Announcement that Massive Bio has been recognized by TIME magazine in the Health Tech AI and Data Analytics category [businesswire.com]. This is a corporate award and does not indicate the clinical stage of a specific drug. - A method to verify antibodies within a few days from predictions made by AI was reported [News-Medical]. This is a technical report at the preclinical (antibody discovery/verification) stage, not information at the clinical trial stage.
Regulations/Approval
No applicable information
Clinical trial implementation status
No relevant information (Specific data regarding trial name, target cancer type, phase, and registration status from ClinicalTrials.gov is not provided at this time)
Japanese movements
Flatiron Health expands the provision of AI-based real-world datasets for breast cancer and NSCLC to Japan [BioSpace]. The headline does not mention any unique developments regarding medical treatment, approval, or clinical trials in Japan.
Remarks from VIPs
The list of important people to be tracked is empty, and there are no quotations with titles in the headlines, so there is no relevant information.
Latest news on AI and rare and incurable diseases
Overview
Only two headlines were provided, and both of them were peripheral articles related to systems and employment, rather than direct information on diagnostics and therapeutic drugs. There are no headlines indicating specific progress regarding diagnostic and therapeutic drugs for designated intractable diseases.
Diagnosis of rare diseases
No applicable information
Gene analysis/genome
No applicable information
Development of therapeutic drugs
No applicable information
Nerve/muscular diseases
No applicable information
Immunology/Collagen disease
No applicable information
Rare metabolic/endocrine diseases
No applicable information
System/Patient Support
- Asura Co., Ltd., which supports the social participation of people with disabilities through "welfare x logistics," realizes AI native recruitment with "MyTalent" (Nico Nico News): This article appears to be an introduction to AI-based services related to employment of people with disabilities, but it is not possible to confirm whether the article is a target disease or a designated intractable disease just by looking at the headline.
Japanese movements
- Report that there was a discussion on the actual state of AI utilization at the Japanese Society of Religious Studies academic conference (Chugai Nippo). The headline does not suggest a direct connection to rare or intractable diseases, but rather appears to be in the context of AI ethics and social debate.
Remarks from VIPs
No applicable information
- Flatiron Health Expands Global Panoramic Datasets With AI-Powered Breast Cancer and NSCLC Real-World Data for the UK, Germany, and Japan — BioSpace09/29 13:46 UTC
- Health system will use AI instead of radiologists for breast imaging 2nd reads — Radiology Business09/29 07:37 UTC
- HR+/HER2- breast cancer: MRI-derived AI score stratifies recurrence risk beyond standard factors — Vera Health09/29 03:18 UTC
- AI-Enhanced Photonic Biosensor Could Help Detect Glioblastoma Tissue — azosensors.com09/29 13:21 UTC
- Sheinelle Jones Horrified by Convincing AI Fake Featuring Her Children — Reality Tea09/29 13:32 UTC
- Latest hospital AI deployments in Singapore and more briefs — Healthcare IT News09/29 11:52 UTC
- Radiology AI firm trims 15% of staff, sees annual revenue surge to $28M — Radiology Business09/29 07:48 UTC
- AI-Powered Liquid Biopsy Emerges as a High-Stakes Frontier — GlobeNewswire09/29 12:23 UTC
- Haga Bioscience, Imagenomix Partner for AI Spatial Biomarker Analysis in Cancer Pathology — Genome Web09/29 13:35 UTC
- BCC Research Highlights Investment Surge in AI-Powered Liquid Biopsy — citybiz09/29 16:25 UTC
- Hospitals replace radiologists with AI for 2nd reads | Imaging AI firm notches $28M in revenue | Low-dose RT for treating KOA — Radiology Business09/29 13:16 UTC
- Pharma sector doubles down on AI to slash costs, timelines — Reuters09/29 00:51 UTC
- TIME Recognizes Massive Bio Among the Top HealthTech Companies in AI and Data Analytics — businesswire.com09/29 14:00 UTC
- From AI prediction to antibody validation in days — News-Medical09/29 10:13 UTC
- [News] Discussion on the current state of AI utilization, sharing specific examples, Japanese Society of Religious Studies Academic Conference — Japanese media09/25 02:41 UTC
- Asura Co., Ltd., which supports the social participation of people with disabilities through "welfare x logistics," has launched "MyTalent," which realizes AI native recruitment. — Japanese media09/29 15:00 UTC
Latest news on AI and cancer treatment
Overview
There was movement in the areas of image diagnosis (lung CT, tumor markers) and drug discovery (molecular adhesive search, peptide search). There have been no reports regarding approval or designation by regulatory authorities, and specific data on clinical trial progress is not included in this collection.
Breast cancer
- OzarksFirst.com (US local news) reported that ``A new AI tool is supporting breast cancer treatment,'' but the headline alone did not specify the number of patients targeted, the method used, or the metrics presented. - An article on oncodaily.com (author: Matthew Kurian) raises the issue of "Who benefits from extended AI treatment?", but the link to breast cancer and specific clinical data cannot be determined from the headline. (All information is headline information only, and figures such as accuracy and detection rate are not shown.)
lung cancer
- MD Anderson (USA) releases an AI model that predicts immunotherapy-related lung inflammation from regular CT images. The report was based on a single facility, and the number of patients, verification method, and accuracy index are unclear from the headline. The evidence stage is presumed to be "single-center research stage," but no details are provided. - Coreline Soft (Korea) expands its Japanese business from "pulmonary nodule AI" to "coronary artery calcification analysis." This is business development news and does not include data on clinical performance.
Malignant brain tumor
No relevant information (The article about the introduction of AI curriculum in the Nye County School District is news in the education field and is judged to be unrelated to brain tumor treatment)
Leukemia/lymphoma
No applicable information
Colon cancer/digestive organ
- A research team at the University of Macau (UM) reports that they have used AI to identify a promising anti-cancer peptide against pancreatic cancer. Although it appears to be at the preclinical (in silico/laboratory level) stage, there is no mention of animal experiments or clinical application stages in the headline. - The Mainichi Shimbun article (an essay on the crossroads of AI) deals with the ethics and social impact of AI in general, and clinical information specific to gastrointestinal cancer cannot be confirmed from the headline.
Rare cancer
- Health Tech World (UK) reports that ``AI tools aim to reduce delays in starting radiation treatments.'' Although the application is expected to be applied to rare cancers such as adenoid cystic carcinoma, the headline does not mention the target cancer types, specific figures for delay reduction, or the stage of evidence.
Diagnosis/Pathology/Image
- GE HealthCare hires a new Chief AI Officer (no personnel news or technical details). - It is reported that AVIS is in talks with a major cancer center in India regarding the introduction of AI (at the stage of business partnership, no clinical data). - Medical Buyer magazine published an article explaining "biomarkers identified by AI." The target cancer type, biomarker type, and verification stage are unclear from the headline.
Treatment selection/drug discovery
- It is reported that the search for molecular glue candidates targeting VAV1 has been accelerated by combining AI and proteomics (Genetic Engineering and Biotechnology News). The stage appears to be preclinical (exploration/identification phase), but detailed verification data are not listed in the headline. - UTHSC (University of Tennessee Health Science Center) published an article on the intersection of academic medicine and AI. There are no specific research results or drug names listed.
Regulations/Approval
No applicable information
Clinical trial implementation status
No relevant information (Information on the individual trial name, target cancer type, phase, and registration status derived from ClinicalTrials.gov is not included in the main text of the news provided this time)
Japanese movements
- eurekalert.org introduces AI research that integrates "disease prediction x classification x treatment" by a joint research team in Japan. Details of the target disease, cancer type, and research stage (preclinical/clinical) are unclear from the headline. - The Japanese edition of Newsweek introduces a statement about the use of AI in medical settings that says it has "saved more than 1,000 lives." The basis for calculating this number, the target disease, and the verification method cannot be confirmed from the article headline alone, and should not be treated as a definitive statement of causality (it is only introduced as a claim in the source article).
Remarks from VIPs
No relevant information (The name of the author of the oncodaily.com article, Matthew Kurian, can be confirmed, but the title and direct quote are not included in the headline. The list of important people being tracked is also blank, so there is no corresponding statement)
Latest news on AI and rare and intractable diseases
Overview
Only two headlines were provided, and there is little information on concrete progress in diagnostic technology, therapeutic drugs, or systems. We can only confirm stock transactions by executives in genome-related companies and reports on a voice AI app for ALS patients.
Diagnosis of rare diseases
No applicable information
Gene analysis/genome
It was reported that the CEO of Tempus AI (TEM, a diagnostic and genome analysis company) sold 10,281 shares of the company's stock at $85 per share based on a pre-determined trading plan. This is a disclosure regarding stock transactions by executives, and the headline does not provide specific details regarding the performance of the company's diagnostic/genome analysis technology or its application to rare disease diagnosis.
Development of therapeutic drugs
No applicable information
Nerve/muscular diseases
A new AI app was introduced that aims to preserve the voice of patients with amyotrophic lateral sclerosis (ALS, which is listed on the list of designated incurable diseases. The notification number cannot be confirmed from the list in this report) (ALS News Today). The headline only indicates the provision of tools related to speech synthesis and storage, but there is no information about the number of cases, evaluation indicators, or development stages (preclinical/clinical trials, etc.) that indicate effectiveness.
Immunology/Collagen disease
No applicable information
Rare metabolic/endocrine diseases
No applicable information
System/Patient Support
No applicable information
Japanese movements
No applicable information
Remarks from VIPs
No relevant information (only disclosure of stock sale by Tempus AI CEO, no report on what was said)
- How New AI Tools Are Helping Treat Breast Cancer — OzarksFirst.com09/29 15:31 UTC
- Matthew Kurian: Who Benefits From Extended AI Therapy? — oncodaily.com09/29 18:27 UTC
- MD Anderson AI Model Predicts Immunotherapy-Related Lung Inflammation From Routine CT Scans — Pulse 2.009/30 00:07 UTC
- Coreline Soft Expands Japan Business from Lung Nodule AI to Coronary Calcium Analysis — Korea IT Times09/30 01:47 UTC
- Nye County school district introducing AI curriculum — WDBJ709/30 05:29 UTC
- UM research team uses AI to identify promising anti-pancreatic cancer peptide — University of Macau09/30 04:21 UTC
- Humanity at an AI crossroads: Will we choose the happy ending? — Japanese media09/29 22:02 UTC
- AI tool aims to cut radiotherapy treatment delays — Health Tech World09/29 09:05 UTC
- GE HealthCare hires chief artificial intelligence officer — Radiology Business09/30 07:09 UTC
- AVIS in AI Talks With Major Indian Cancer Center — 동아비즈니스리뷰09/29 04:57 UTC
- Decoding AI-identified biomarker — Medical Buyer09/28 12:59 UTC
- AI and Proteomics Accelerate VAV1 Molecular Glue Discovery — Genetic Engineering and Biotechnology News09/30 02:13 UTC
- Where Academic Healthcare Meets AI — UTHSC News09/29 18:32 UTC
- Disease prediction x classification x treatment evolving with AI - the future of therapeutics opened up through collaborative research — eurekalert.org09/30 01:49 UTC
- Utilizing AI in the medical field that has “saved more than 1,000 lives” | Newsweek Japan Official Site — newsweekjapan.jp09/29 23:00 UTC
- A trading plan governed the sale of 10,281 Tempus AI (TEM) shares by its diagnostics CEO at $85 each. — Stock Titan09/29 20:15 UTC
- New AI app helps people with ALS keep their own voices — ALS News Today09/29 14:34 UTC